Alexion Pharma (ALXN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016
February 3, 2016 6:30 AM EST- Total Revenues of $2.604 Billion; Increased 21% Year-on-Year; 29% Increase Year-on-Year on Constant Currency Basis -
- Soliris® (eculizumab) Net Product Sales of $2.590 Billion -
- Strensiq® (asfotase alfa) and Kanuma (sebelipase alfa) Approved in the United States in Q4 with Launches Underway; Two Rare Pediatric Disease Priority Review Vouchers Granted -
- Completed Enrollment in MG and DGF Registration Programs with Eculizumab; Advanced NMOSD Registration Trial -
- Completed Enrollment in Phase 1/2 Study of ALXN1210 in Patients with PNH -
- Six-Month Data from SBC-103 Phase 1/2... More
